Zymeworks Financial Statements
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zymeworks revenue and earnings
In fiscal 2025, Zymeworks generated $106.0 million in revenue, up 38.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Zymeworks reported a net loss of $81.1 million, compared with a loss of $122.7 million a year earlier. Operating margin was -87.3%.
Diluted earnings per share came in at -$1.08. Over the last 5 fiscal years, ZYME's revenue has grown at a 22.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Zymeworks income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 105.97M | 76.30M | 76.01M | 412.48M | 26.68M | 38.95M |
| Revenue growth (YoY) | +38.87% | +0.38% | -81.57% | +1446.03% | -31.50% | — |
| Research & Development | 137.00M | 134.62M | 143.62M | 208.60M | 199.75M | 171.20M |
| Operating Income | -92.55M | -137.11M | -138.05M | 130.53M | -215.63M | -187.47M |
| Other Income (Expense) | -559.00K | 558.00K | -894.00K | 1.11M | 1.31M | 1.65M |
| Pretax Income | -79.75M | -116.61M | -119.24M | 135.23M | -212.36M | -180.12M |
| Income Tax | 1.38M | 6.08M | -568.00K | 10.89M | -516.00K | 429.00K |
| Net Income | -81.13M | -122.69M | -118.67M | 124.34M | -211.84M | -180.55M |
| Net Income growth (YoY) | — | — | -195.44% | — | — | — |
| EPS (Basic) | -1.08 | -1.62 | -1.72 | 1.91 | -4.11 | -3.58 |
| EPS (Diluted) | -1.08 | -1.62 | -1.72 | 1.90 | -4.61 | -3.58 |
| Shares Outstanding (Basic) | 75.40M | 75.85M | 68.86M | 65.19M | 51.55M | 50.38M |
| Shares Outstanding (Diluted) | 75.41M | 75.88M | 68.86M | 65.25M | 52.13M | 50.38M |
| EBITDA | -88.88M | -132.92M | -130.59M | 136.75M | -211.89M | -184.11M |
| Operating Margin | -87.34% | -179.69% | -181.62% | 31.64% | -808.22% | -481.29% |
| Net Margin | -76.56% | -160.80% | -156.13% | 30.14% | -794.01% | -463.54% |
This table shows 6 annual periods of Zymeworks's income statement, from FY 2025 back to FY 2020, across 14 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ZYME's reporting calendar. What is a income statement?